The company’s common stock raise in OTCQB coincides with its recent receipt of DTC eligibility, enhancing the ability of US investors to become Ketamine One shareholders.
Vancouver, British Columbia, Jan. 12, 2022 (Globe Newswire) – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTCQB: KONEF) (Frankfurt: MY0), a company focused on integrating clinical practice and becoming a North American leader in mental health treatments, is pleased to announce that its joint stock has been successfully listed (“menu upFrom OTC Pink Sheet Open Market to OTCQB Venture Market (“)OTCQB(“) by OTC Markets Group Inc. (“OTC Markets“). The company’s common stock will begin trading in OTCQB under the symbol “KONEF” as of the market opening on January 12, 2022. The top listing completes the company’s previous receipt of DTC eligibility. Ketamine One’s common stock will continue to trade on the NEO Stock Exchange under the symbol “MEDI” and the Stock Exchange Frankfurt Stock Exchange under the symbol “MY0”.
OTCQB, operated by OTC Markets, offers transparent trading in entrepreneurship and development stage companies that have passed the minimum bid price test, are current in their financial reporting and have gone through an annual verification and management certification process. The United States recognizes OTCQB (“we”) The Securities and Exchange Commission as an established public market that provides public information for the analysis of the value of securities. These standards provide a strong foundation for transparency, as well as technology and regulations to improve the trading experience for investors.
Ketamine One has a verified profile of 12g3-2(b) approved by OTC Markets. Investors or other interested parties in the United States can obtain real-time quotes for Ketamine One as well as access the latest news and other information at www.otcmarkets.com. Contributors will now also have greater access to information via the OTC Disclosure and News Service, as well as transparent pricing through the full depth of the book with real-time Level 2 quotes.
“We are pleased that Ketamine One common stock has been accepted into OTCQB by OTC Markets. Listing our shares on the OTCQB is important because it makes it easier for US investors to obtain information about our securities and purchase our shares. Along with DTC eligibility, it allows US residents interested in the mental health revolution to become contributors and participate in our growth,” said Adam Devitt, interim CEO of Ketamine One. “Now with the listing of our common stock on NEO, Frankfurt Stock Exchange and OTCQB, it is easier than ever for investors in the world’s major capital markets to become owners of Ketamine One securities,” added Mr. Devitt.
About Ketamine One
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on integrating clinics to become the North American leader in mental health treatments. It works to provide the critical infrastructure needed to develop and deliver advanced mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further enhance the highly retail industry. KGK Science Inc. is the company’s wholly owned contract research division, which puts it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in the pharmaceutical, hemp and emerging psychedelic industries. As a group project, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health treatment.
On behalf of the:
Adam Devitt, Interim CEO
For more information, please contact:
Nick Cusick, Investor Relations
Phone: 1-844-PHONE-K1 (1-844-746-6351)
Notice regarding forward-looking information:
This press release contains forward-looking statements, including but not limited to statements relating to the Company’s business, assets, or investments, as well as other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no guarantee of occurrence of the plans, intentions or expectations on which they are based. By their nature, forward-looking statements involve many assumptions, known and unknown risks and uncertainties, general and specific, that contribute to the possibility that predictions, forecasts, projections and other forward-looking statements may not occur, which may cause an actual occurrence. Performance and results in future periods may differ materially from any estimates or expectations of future performance or results expressed or implied in these forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, and investors’ interest in the company’s business and prospects.
The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. In addition, the Company undertakes no obligation to comment on forecasts or statements made by third parties in connection with the matters discussed above.
Source: KetamineOne Capital Limited